moving nanomedicine towards h2020 · moving nanomedicine towards h2020 patrick boisseau business...
TRANSCRIPT
Moving Nanomedicine towards H2020
Patrick BOISSEAU Business Development Nanomedicine, CEA-Leti, Grenoble (FR)
Chair of Working Group Nanodiagnostics, ETPN
• Background
• Nanomedicine value chain
• Towards translational nanomedicine
• The future PPP Health
• Work plan 2012-2013
• Conclusions
2
Outline
05/11/2012 ETPN General Assembly London
• Only 14 months left before beginning H2020
• H2020 focuses on innovation and translation to industry
• Slow move of nanomedicine towards industrialization; increase of
– Clinical trials
– Approved products
3
Background
05/11/2012 ETPN General Assembly London
44 marketed Nano-delivery products Product Generic Formulation Indication Manufacturer
Abraxane Paclitaxel Polymeric
nanoparticles
Cancer
chemotherapy Celgene
Abelcet Amphotericin B Liposomal
formulation
Fungal infections
Elan/Alkermes, Enzon,
Cephalon
Adagen Adenosine
deaminase PEGylation
Enzyme replacement
therapy
Enzon, Sigma-Tau
AmBisome Amphotericin B Liposomal
Formulation
Oral and perioral
infections
Astellas/Gilead
Sciences
Amphotec Amphotericin B Liposomal
Formulation
Oral and perioral
infections
Three Rivers
Pharmaceuticals/ALZA
Avinza Morphine
sulphate
nanocrystal
formulation
Moderate to severe
pain Elan/Alkermes, Pfizer
Copaxone Glatiramer
acetate
Copolymer of lglutamic
acid, lalanine, l-tyrosine
and l-lysine)
Multiple sclerosis Teva Pharmaceuticals
Curosurf Poractant alfa Liposome Neonatal respiratory
distress
Chiesi Farmaceutici
SpA
DaunoXome Daunorubicin PEGylated liposome
Formulation
Cancer
chemotherapy Gilead Sciences
DepoCyt Cytarabine Sustained-release
Liposomes
Cancer
chemotherapy SkyePharma/Enzon
Depodur Morphine
sulphate Liposome
Pacira
Pharmaceuticals
Pacira
Pharmaceuticals
Diprivan Propofol Liposomes Induction of
anesthesia AstraZeneca
Doxil/CaelyX Doxorubicin PEGylated liposome
Formulation
Cancer
chemotherapy
ALZA/ OrthoBiotech/
Schering Plough
Elestrin Elestrin Estradiol
gel
Phosphate
nanoparticles
Menopausal
symptoms BioSante
Elyzol Metronidazole Dental gel Parodontitis Camurus Camurus
Emend Aprepitant Nanocrystal
Formulation
Anti-emetic
Merck & Co+
Elan/Alkermes
Epaxal Hepatitis A
vaccine Virosome technology
Prevention of
Hepatitis A infection Berna Biotech
Episil Bioadhesive
barrier Fluidcrystal Oral pain Sinclair/Teva
Estrasorb Estradiol gel Micellar
Nanoparticles
Menopausal
symptoms
Novavax/Espirit
Pharma
Focalin XR Dexmethylphen
idate hcl Nanocrystals ADHD
Novartis
Élan/Alkermes
Fosrenol Lanthanum
carbonate
Inorganic
Nanoparticles
End-stage renal
disease Shire
Genexal PM Paclitaxel Polymeric micelles Cancers Samyang
Product Generic Formulation Indication Manufacturer
Indaflex Indomethacin
Solid/lipid
nanoparticles Osteoarthritis AlphaRx
Inflexal V Subunit influenza
vaccine Virosome Influenza prophylaxis Crucell
Invega
Sustenna Paliperidone Nanocrystal Antipsychotic Janssen
Macugen Pegaptanib Pegylated anti-vegf
aptamer
Age-related
macular
degeneration
OSI Pharmaceuticals/
Pfizer
Myocet Doxorubicin
citrate complex Liposome encapsulated Cancer chemotherapy
Cephalon/Zeneus
Pharma/ Sopherion
Therapeutics
Megace ES Megestrol acetate Nanocrystal formulation Cancer therapy Elan/Alkermes+Par+Bristol-
Myers Squibb
MuGard Hydrogel mouth
rinse
Nanogel
Head and neck cancers Access Pharma
Naprelan Naproxen Nanocrystal formulation Arthritis, gout Elan/Alkermes
Nanoxel Paclitaxel Polymeric nanoparticles Cancer chemotherapy Dabur Pharma
Neulasta Filgrastim Pegylation Neutropenia Amgen
Oncospar Oncospar PEG-
Lasparaginase
Pegylation
Cancers
Enzon/Schering-
Plough
Pegasys Peginterferon alfa
2a
Pegylation
Hepatitis B, hepatitis C Roche/Nektar
PegIntron Peginterferon alfa
2b
Pegylation
Chronic hepatitis C Schering-Plough
Rapamune Sirolimus Nanocrystal formulation Immunosuppression Wyeth Élan/Alkermes
Renagel Sevelamer hcl Poly (allylamine) resin Hyperphosphatemia in
hemodialysis Genzyme
Salinum
Potassium,
magnesium,
chlorine
Oral liquid Xerostomia
Somavert Pegvisomant Polymer protein conjugate Acromegaly Pfizer
Ritalin LA Methylphenidate
Hcl
Pulsatile release
Nanocrystal formulation ADHD Elan/Novartis
Survanta Beractant Liposome encapsulated Neonatal respiratory
distress Abbott
Tricor Fenofibrate Nanocrystal formulation Lipid reduction Abbott Élan/Alkermes
Triglide Fenofibrate Nanocrystal formulation Lipid reduction
SkyePharma/ First Horizon
Pharmaceuticals/Sciele
Pharma
Verelan/
Verelan
PM
Verapamil Elan’s SODAS
Multiparticulate technology Hypertension Elan/Alkermes Schwarz
Source BCC Research
05/11/2012 ETPN General Assembly London 4
18 marketed Pharmaceutical products
Product Composition Indication Company
Annual
Sales
($ Millions)
Abelcet Amphotericin B/lipid Fungal infections Enzon 23
Ambisome Liposomal
amphotericin B Fungal infections Gilead 350
Doxil, Caelyx Liposomal
doxorubicin Kaposi’s sarcoma Ortho, Schering-Plough 360
Depocyt Liposomal cytarabine Cancer Skyepharma 170
Visudyne Liposomal verteporfin
Age-related macular
degeneration QLT, Novartis 150
Estrasorb Estradiol in micelles Menopause Novavax 130
Adagen PEG-adenosine
deaminase Immunodeficiency Enzon 33
Neulasta PEG-GCSF Neutropenia Amgen 500
Oncospar PEG-asparaginase Leukemia Enzon 65
Pegasys PEG- α -interferon 2a Hepatitis C Nektar, Roche 1,650
PEG-Intron PEG-α -interferon 2b Hepatitis C Enzon, Schering-Plough 975
Macugen Pegylated anti-VEGF
aptamer
Age-related macular
degeneration OSI Pharmaceuticals, Pfizer 175
Somavert PEG-HGH Acromegaly Nektar, Pfizer 325
Copaxone Copolymer of amino-acids Multiple sclerosis TEVA 3,250
Renagel Crosslinked
poly(allylamine) resin
Chronic kidney
Disease Genzyme 575
Megace ES Nanocrystalline
megestrol acetate Eating disorders Elan, Par 55
Rapamune Nanocrystalline
sirolimus Immunosuppression Elan, Wyeth 340
Abraxane Paclitaxel proteinbound
nanoparticles Cancer Abraxis, AstraZeneca 675
05/11/2012 ETPN General Assembly London 5
15 marketed Imaging/diagnostic & biomaterial Product Composition Indication Company
In vivo Imaging
Resovist Iron nanoparticles Liver tumors Schering, Berlin
Feridex/Endorem
Iron nanoparticles
Liver tumors
Advanced Magnetics,
Guerbet
Gastromark/Lumirem
Iron nanoparticles
Imaging abdominal
structures
Advanced Magnetics,
Guerbet
In Vitro Diagnostics
Lateral flow tests
Colloidal gold
Pregnancy, ovulation, HIV
etc
British Biocell,
Amersham/GE,
Nymox
Clinical cell separation
Magnetic nanoparticles
Immunodiagnostics
Dynal/InVitrogen,
Miltenyl Biotec,
Immunicon
Biomaterials
Ceram X duo Nanoparticle composite Dental filling material Dentspley
Filtek Supreme Nanoparticle composite Dental filling material 3M Espe
Mondial
Nanoparticle-containing
dental prosthesis
Dental restoration Heraeus Kulzer
Premise
Nanoparticle composite Dental repair
Sybron Dental Specialities
Tetric Evoceram Nanoparticle composite Dental Repair Ivoclar Vivadent
Ostim Nano-hydroxy apatite Bone defects Osartis
Perossal Nano-hydroxy apatite Bone defects Aap implantate
Vitoss Nano-hydroxy apatite Bone defects Orthovita
Acticoat Silver nanoparticles Antimicrobial wound care Nucryst
Active Implants
Pacemaker Fractal electrodes Heart failure Biotronik
05/11/2012 ETPN General Assembly London 6
http://www.centerwatch.com/drug-information/fda-approvals/drug-areas.aspx?mp=empty
>70 Nanomedical Products in Clinical trials Cardiovascular
Diseases Endocrinology Hematology
Immunology
Infectious Diseases Musculoskeletal Neurology Oncology
NCE Brilinta (ticagrelor); AstraZeneca; For the
reduction of thrombotic events in patients with
acute coronary syndrome, Approved July 2011
NCE Afinitor (everolimus); Novartis; For the
treatment of advanced pancreatic
neuroendocrine tumors, Approved May 2011
NANO Adcretris (brentuximab vedotin); Seattle
Genetics; For the treatment of Hodgkin
lymphoma and anaplastic large cell lymphoma,
Approved August 2011
NCE Arcapta (indacaterol maleate inhalation
powder); Novartis; For the treatment of airflow
obstruction resulting from chronic obstructive
pulmonary disease, Approved July 2011
AB Actemra (tocilizumab); Genentech; For the
treatment of systemic juvenile idiopathic arthritis,
Approved April 2011
NCE Abstral (fentanyl sublingual tablets);
ProStrakan; For the treatment of breakthrough
cancer pain in opioid-tolerant patients, Approved
January 2011
NCE Abstral (fentanyl sublingual tablets);
ProStrakan; For the treatment of breakthrough
cancer pain in opioid-tolerant patients, Approved
January 2011
NCE Edarbi (azilsartan medoxomil); Takeda; For
the treatment of hypertension, Approved
February 2011
NCE Juvisync (sitagliptin and simvastatin);
Merck; For the treatment of type II diabetes,
Approved October 2011
NCE Ferriprox (deferiprone); Apotex; For the
treatment of transfusional iron overload due to
thalassemia, Approved October 2011
AB Benlysta (belimumab); Human Genome
Sciences; For the treatment of systemic lupus
erythematosus, Approved March 2011
NCE Duexis (ibuprofen and famotidine); Horizon
Pharma; For the relief of rheumatoid arthritis
and osteoarthritis and prevention of gastric
ulcers, Approved April 2011
NCEGralise (gabapentin); Abbott; For the
treatment of postherpetic neuralgia, Approved
February 2011
NANO Adcretris (brentuximab vedotin); Seattle
Genetics; For the treatment of Hodgkin
lymphoma and anaplastic large cell lymphoma,
Approved August 2011
NCE Xarelto (rivaroxaban); Bayer; For the
prophylaxis of deep vein thrombosis during knee
or hip replacement surgery, Approved July 2011
NCE Sutent (sunitinib malate); Pfizer ; For the
treatment of pancreatic neuroendocrine tumors,
Approved May 2011
AB Soliris (eculizumab); Alexion; For the
treatment of atypical hemolytic uremic
syndrome, Approved September 2011
NCE Complera
(emtricitabine/rilpivirine/tenofovir disoproxil
fumarate); Gilead; For the treatment of HIV-1 in
treatment-naive adults, Approved August of
2011
Nephrology
Urology
NCE Horizant (gabapentin enacarbil);
GlaxoSmithKline; For the treatment of restless
legs syndrome, Approved April 2011
NCE Afinitor (everolimus); Novartis; For the
treatment of advanced pancreatic
neuroendocrine tumors, Approved May 2011
Dermatology
Plastic Surgery
NCE Tradjenta (linagliptin); Boehringer
Ingelheim; For the treatment of type II diabetes,
Approved May 2011
NCE Xarelto(rivaroxaban); Bayer; For the
prophylaxis of deep vein thrombosis during knee
or hip replacement surgery, Approved July 2011
NCE Daliresp (roflumilast); Forest
Pharmaceuticals; For the treatment of chronic
obstructive pulmonary disease, Approved
February 2011
NBE Nulojix (belatacept); Bristol-Myers Squibb;
For the prevention of organ rejection following
kidney transplant, Approved June 2011
NCE Lazanda (fentanyl citrate) nasal spray;
Archimedes; For the management of
breakthrough cancer pain, Approved June 2011
NCE Lazanda (fentanyl citrate) nasal spray;
Archimedes; For the management of
breakthrough cancer pain, Approved June 2011
peptide Firazyr (icatibant); Shire; For the
treatment of acute attacks of hereditary
angioedema, Approved August of 2011 Gastroenterology Otolaryngology NCE Dificid (fidaxomicin); Optimer
Pharmaceuticals; For the treatment of
Clostridium difficile-associated diarrhea,
Approved May 2011
AB Soliris (eculizumab); Alexion; For the
treatment of atypical hemolytic uremic
syndrome, Approved September 2011
NCE Onfi (clobazam); Lundbeck; For the
adjunctive treatment of seizures associated with
Lennox-Gastaut syndrome, Approved October
2011
NCE Sutent (sunitinib malate); Pfizer; For the
treatment of pancreatic neuroendocrine tumors,
Approved May 2011
NCE Gralise (gabapentin); Abbott; For the
treatment of postherpetic neuralgia, Approved
February 2011
NCE Afinitor (everolimus); Novartis; For the
treatment of advanced pancreatic
neuroendocrine tumors, Approved May 2011
NCE Vandetanib (vandetanib); Astra
Zeneca; For the treatment of thyroid
cancer, Approved April 2011
NCE Edurant (rilpivirine); Tibotec; For the
treatment of HIV-1, Approved May 2011 Pharmacology
Toxicology
NCE Oxecta (oxycodone HCl); Pfizer; For the
management of acute and chronic moderate to
severe pain, Approved June 2011
NANO Sylatron (peginterferon alfa-2b); Merck;
For the treatment of melanoma, Approved April
2011
CELL laViv (azficel-T); Fibrocell Science; For the
improvement of nasolabial fold wrinkles in
adults, Approved June 2011
NCE Dificid (fidaxomicin); Optimer
Pharmaceuticals; For the treatment of
Clostridium difficile-associated diarrhea,
Approved May 2011
Pulmonary
Respiratory Diseases
Peptide Firazyr (icatibant); Shire; For the
treatment of acute attacks of hereditary
angioedema, Approved August of 2011
NCE Oxecta (oxycodone HCl); Pfizer;
For the management of acute and
chronic moderate to severe pain,
Approved June 2011
NCE Potiga (ezogabine); Valeant
Pharmaceuticals; For the treatment of partial-
onset seizures, Approved June 2011
NCE Vandetanib (vandetanib); Astra Zeneca;
For the treatment of thyroid cancer, Approved
April 2011
NANO Sylatron (peginterferon alfa-2b); Merck;
For the treatment of melanoma, Approved April
2011
NCE Duexis (ibuprofen and famotidine);
Horizon Pharma; For the relief of rheumatoid
arthritis and osteoarthritis and prevention of
gastric ulcers, Approved April 2011
NCE Arcapta (indacaterol maleate
inhalation powder); Novartis; For the
treatment of airflow obstruction
resulting from chronic obstructive
pulmonary disease, Approved July
2011
NCE Gralise (gabapentin); Abbott; For the
treatment of postherpetic neuralgia, Approved
February 2011
Rheumatology
NCE Viibryd (vilazodone hydrochloride); Clinical
Data; For the treatment of major depressive
disorder, Approved January 2011
NCE Xalkori (crizotinib); Pfizer; For the
treatment of ALK+ non-small cell lung cancer,
Approved August of 2011
antibody Yervoy (ipilimumab); Bristol-Myers
Squibb; For the treatment of metastatic
melanoma, Approved March 2011
17 NCE Incivek (telaprevir); Vertex; For the
treatment of genotype 1 chronic hepatitis C,
Approved May 2011
NCE Daliresp (roflumilast); Forest
Pharmaceuticals; For the treatment of
chronic obstructive pulmonary disease,
Approved February 2011
NCE Incivek (telaprevir); Vertex; For the
treatment of genotype 1 chronic hepatitis C,
Approved May 2011
AB Actemra (tocilizumab); Genentech;
For the treatment of systemic juvenile
idiopathic arthritis, Approved April 2011
Pediatrics
Neonatology
AB Yervoy (ipilimumab); Bristol-Myers Squibb;
For the treatment of metastatic melanoma,
Approved March 2011
NCE Zelboraf (vemurafenib); Roche; For the
treatment of BRAF + melanoma, Approved
August of 2011
NCE Rectiv (nitroglycerin) ointment 0.4%;
ProStrakan; For the treatment of chronic anal
fissure, Approved June 2011
NCE Xalkori (crizotinib); Pfizer; For the
treatment of ALK+ non-small cell lung
cancer, Approved August of 2011
NBE Nulojix (belatacept); Bristol-Myers Squibb;
For the prevention of organ rejection following
kidney transplant, Approved June 2011
NCE Duexis (ibuprofen and
famotidine); Horizon Pharma; For the
relief of rheumatoid arthritis and
osteoarthritis and prevention of gastric
ulcers, Approved April 2011
AB Actemra (tocilizumab); Genentech;
For the treatment of systemic juvenile
idiopathic arthritis, Approved April 2011
NCE Zelboraf (vemurafenib); Roche; For the
treatment of BRAF + melanoma, Approved
August of 2011
Obstetrics
Gynecology
NCE Sutent (sunitinib malate); Pfizer; For the
treatment of pancreatic neuroendocrine tumors,
Approved May 2011 Pharmacology
Toxicology
NCE Victrelis (boceprevir); Merck; For the
treatment of chronic hepatitis C genotype 1,
Approved May 2011
NCE Daliresp (roflumilast); Forest
Pharmaceuticals; For the treatment of
chronic obstructive pulmonary disease,
Approved February 2011
NCE Zytiga (abiraterone acetate); Centocor
Ortho Biotech; For the treatment of prostate
cancer, Approved May 2011
NCE Makena (hydroxyprogesterone caproate
injection); Hologic; For the prevention of risk of
preterm birth, Approved February 2011
NCE Victrelis (boceprevir); Merck; For the
treatment of chronic hepatitis C genotype 1,
Approved May 2011
NCE Oxecta (oxycodone HCl); Pfizer;
For the management of acute and
chronic moderate to severe pain,
Approved June 2011
NCE Onfi (clobazam); Lundbeck; For
the adjunctive treatment of seizures
associated with Lennox-Gastaut
syndrome, Approved October 2011
05/11/2012 ETPN General Assembly London 7
Global nanomedicine market
• $63.8 billion in 2010 and $72.8 billion in 2011
– +14%
• Expected growth to $130.9 billion by 2016
– +12.5%/year between years 2011 and 2016
• Nanomedicine: 10% of pharma sales Source: BBC Research
05/11/2012 8 ETPN General Assembly London
11
The nanomedicine value chain
Patient
Needs
• Clinical trials
• Translation
• Regulatory Issues
• Reimbursement
• Qualified products
and services
• Qualified products
and services
Basic
Research
Applied
R&D
Industrial
Implement.
Clinical
Implement.
05/11/2012 ETPN General Assembly London
12
The nanomedicine stakeholders
Basic
Research
Applied
R&D
Industrial
Implement.
Clinical
Implement.
05/11/2012
Academia
Research & technology institutes
SMEs
SMEs Large
companies Hospitals
Participation to ETPN
Players
ETPN General Assembly London
Academia
Nano based technologies,
research, concepts ….
Industry
Market
Translation hub
Pre-clinical studies, Clinical
studies, IP, Manufacturing,
Business Development, Regulation
The situation in Europe
Innovation
05/11/2012 13 ETPN General Assembly London
• Liaising Academia with industry
• Establishing a supply chain of innovative SMEs
• Support of the early preclinical or clinical proofs of concepts before transfer to large companies
What does translation mean?
05/11/2012 ETPN General Assembly London 14
• Education of academia to industrial development constraints
• Evaluation of projects with the industrial perspective
• Better connection/interface between SMEs and large companies
What does translation require? (from an industrial perspective)
05/11/2012 ETPN General Assembly London 15
Towards an open innovation model
Large companies
Academia
SMEs
05/11/2012 ETPN General Assembly London 16
Integration in the PPP Health model
PPP Health (EC/industry)
Diagnostic (industry)
Nanomedicine (industry, academy)
Pharmaceuticals (industry)
Specific activities
Joint activities
Specific activities
Specific activities
Joint activities
05/11/2012 ETPN General Assembly London 17
• Nano-characterization
– Physical, chemical and biological evaluation
– Synchronization with EMA
– Mirror site to US/NCL
• Manufacturing of clinical batches
– Scale up of manufacturing process
– From lab to GMP unit
• Regulatory issues
Specific activities of nanomedicine
05/11/2012 ETPN General Assembly London 18
• Education on translation
– Industrial translation experts
– Paid by EC to industry
• Show case of SMEs to large companies
• Joint R&D projects
• Early pre/clinical trials
Joint actions with pharma and diag
05/11/2012 ETPN General Assembly London 19
• R&D infrastructure – With trained team and facilities working according to the highest standard
– From early non clinical proof of concept to end of Phase 1/Pilot Study
• Services – Characterization (Phys., Chem. & Bio)
– Industrial prototyping
– Industrialization, early manufacturing
– Safety package
– Pre-clinical development
– Regulatory
– QC
– Research to sustain development
– Market access
05/11/2012 20
The nanomed translational infrastructure
ETPN General Assembly London
Facilitate the emergence
of a
profitable nanomedicine
sector in Europe
05/11/2012 21
Our objective
ETPN General Assembly London
❶ Increase resources of ETPN
❷ Bridge academia, SMEs and
large companies
❸ Make nanomed products ready for clinical trials
❹ Shape R&D funding
Priorities for 2012-2013
05/11/2012 ETPN General Assembly London 22
• Membership
– Strong focus on SMEs
• Objective: +25 SMEs
– Contact with large companies
• Objective : + 2-3 large companies
• Management of EU projects
– Nanomed 2020
– Translation infrastructure
❶ Resources of ETPN Urgent action needed
05/11/2012 ETPN General Assembly London 23
• Education
– Tutorials on translation
– Undergraduate courses on translation
• Expose SMEs’ early clinical proofs of concept to large companies
• Evaluation of translation projects with participation of industry
• Tutoring of translation project with participation of industry
❷ Bridge academia, SMEs and companies
05/11/2012 ETPN General Assembly London 24
• Nanomed Translation (Hub) Infrastructure
– Characterization Lab
– GMP Manufacturing
– Support to a few selected early phase clinical trials Phase I
– …
❸ Make nanomed products ready for
clinical trials
05/11/2012 ETPN General Assembly London 25
• Update the Strategic Innovation & Research Agenda (ex-SRA)
– For the EC
– For the PPP Health
• Synchronize the SIRA with EFPIA and COCIR
• Contribute to the KETs programme (see Heico’s lecture)
• Contribute to the EC/Infrastructure programme
❹ Shape R&D funding
05/11/2012 ETPN General Assembly London 26
• Liaise with EC
– DG Research & Innovation
• Health
• NMP
– DG Infrastructure
• Synchronize the ETPN White Paper
– with EFPIA and COCIR
• Coordinate with Members States
– Mirror Group
05/11/2012 27
ETPN strategy towards H2020
ETPN General Assembly London
Team up with other stakeholders and groups
Implementation of joint activities:
• European Summit for
Nanomedicine
• Policy – Industry Tables
• High-Level meetings on
Future Medicine
• Other actions …
05/11/2012 28 ETPN General Assembly London
29
ETPN as mediator – the translation triangle 1. Nanomedicine into clinical practice via industry
2. Align up-stream R&D with industrial needs
3. Bridge academia and industry and clinicians on
Market needs
S&T bottlenecks
Approval process
Technology roadmaps
4. Suggest industry inspired call topics to the EC and to ERANET EuroNanoMed
Clin. trial Clin. trial
Clinics
Academia Industry Translation
Clin. trial Clin. trial
CLINAM
05/11/2012 ETPN General Assembly London
05/11/2012 30
Federating the nanomed community
CLINAM
ETPN General Assembly London
IT’S NOW OR
NEVER 05/11/2012 ETPN General Assembly London 31
Conclusion
Let’s be ambitious
05/11/2012 32 ETPN General Assembly London
For more information visit: www.etp-nanomedicine.eu or contact [email protected]
Thank you for your support
and attention